Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 19, 2026, 8:24 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 601–624 of 4,242 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Immune Deficiency Disorder Clear all
Completed No phase listed Observational Accepts healthy volunteers

Antiretrovirals and Rate of Progression in Carotid Artery Intima-medial Thickness in HIV

NCT00575939
View directory record Official record
Conditions
HIV Infections, Atherosclerosis
Interventions
Not listed
Lead sponsor
University Hospitals Cleveland Medical Center
Other
Eligibility
18 Years and older
Enrollment
120 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2014
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Dec 19, 2014 · Synced Oct 19, 2026, 8:24 PM EDT
Completed Phase 2 Interventional

Dose Ranging Trial of Tipranavir/Ritonavir in Treatment-Experienced HIV Infected Individuals

NCT00034866
View directory record Official record
Conditions
HIV Infections
Interventions
Protease inhibitor tipranavir
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
18 Years and older
Enrollment
165 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002
U.S. locations
50
States / cities
Phoenix, Arizona • Fountain Valley, California • Long Beach, California + 40 more
Source: ClinicalTrials.gov public record
Updated Sep 20, 2005 · Synced Oct 19, 2026, 8:24 PM EDT
Not listed Not applicable Interventional

A Study of Foscarnet in the Treatment of Cytomegalovirus (CMV) of the Eyes in Patients With AIDS Who Have Not Had Success With Ganciclovir

NCT00002301
View directory record Official record
Conditions
Cytomegalovirus Retinitis, HIV Infections
Interventions
Foscarnet sodium
Drug
Lead sponsor
Astra USA
Industry
Eligibility
18 Years to 65 Years
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jun 24, 2005 · Synced Oct 19, 2026, 8:24 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Computer-Assisted Tailored Cue-card Health [CATCH] Study

NCT01170741
View directory record Official record
Conditions
Human Immunodeficiency Virus, STDs, Hepatitis, Viral, Human
Interventions
Tailored Cue Cards
Behavioral
Lead sponsor
RTI International
Other
Eligibility
18 Years and older
Enrollment
122 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2012
U.S. locations
1
States / cities
Raleigh, North Carolina
Source: ClinicalTrials.gov public record
Updated Oct 25, 2012 · Synced Oct 19, 2026, 8:24 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Fostering Resilience to Psychosocial and HIV Risk in Indian MSM

NCT02556294
View directory record Official record
Conditions
HIV Infection, Sexual Behavior, Health Behavior
Interventions
Self-acceptance based intervention, HIV/STI counseling and testing
Behavioral
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years and older · Male only
Enrollment
608 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2019
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Oct 23, 2019 · Synced Oct 19, 2026, 8:24 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Phase I Clinical Trial to Evaluate: Part A. The Safety of MTP-PE/MF59 Adjuvant Emulsion. Part B. The Safety and Immunogenicity of Env 2-3, a Yeast Derived Recombinant Envelope Protein of Human Immunodeficiency Virus-1, in Combination With MTP-PE/MF59

NCT00000972
View directory record Official record
Conditions
HIV Infections, HIV Seronegativity
Interventions
MTP-PE/MF59, Env 2-3
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 50 Years
Enrollment
64 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
Ends 1992
U.S. locations
3
States / cities
Rochester, New York • Nashville, Tennessee • Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Nov 4, 2021 · Synced Oct 19, 2026, 8:24 PM EDT
Completed Not applicable Interventional

The Safety and Effectiveness of r-HuEPO in Patients With AIDS or Advanced AIDS-Related Complex (ARC) Who Are Anemic

NCT00002303
View directory record Official record
Conditions
HIV Infections, Cytopenias
Interventions
Epoetin alfa
Drug
Lead sponsor
Ortho Pharmaceuticals
Industry
Eligibility
18 Years to 75 Years
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
1
States / cities
Raritan, New Jersey
Source: ClinicalTrials.gov public record
Updated Jun 24, 2005 · Synced Oct 19, 2026, 8:24 PM EDT
Completed Not applicable Interventional Results available

Web-Based Cognitive Behavioral Stress Management for Latino Sexual Minority Men Living With HIV and Cancer

NCT03993054
View directory record Official record
Conditions
HIV/AIDS, Cancer
Interventions
Culturally-tailored cognitive behavioral stress management
Behavioral
Lead sponsor
University of Miami
Other
Eligibility
18 Years and older · Male only
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Jun 2, 2025 · Synced Oct 19, 2026, 8:24 PM EDT
Recruiting Phase 3 Interventional

Study of Oral Deucrictibant XR Tablet for Prophylaxis and Deucrictibant Soft Capsule for On-Demand Treatment of Angioedema Attacks in Adults With Acquired Angioedema Due to C1 Inhibitor Deficiency

NCT07266805
View directory record Official record
Conditions
Acquired Angioedema Due to C1-Inhibitor Deficiency (AAE-C1-INH)
Interventions
Deucrictibant, Placebo
Drug
Lead sponsor
Pharvaris Netherlands B.V.
Industry
Eligibility
18 Years and older
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
4
States / cities
San Diego, California • Walnut Creek, California • St Louis, Missouri + 1 more
Source: ClinicalTrials.gov public record
Updated Sep 21, 2026 · Synced Oct 19, 2026, 8:24 PM EDT
Completed Phase 3 Interventional

A Comparison of Zidovudine (AZT) Used Alone or in Combination With Didanosine (ddI) or Dideoxycytidine (ddC) in HIV-Infected Patients

NCT00001022
View directory record Official record
Conditions
HIV Infections
Interventions
Zidovudine, Zalcitabine, Didanosine
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
13 Years and older
Enrollment
1,200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Ends 1995
U.S. locations
16
States / cities
San Francisco, California • Denver, Colorado • New Haven, Connecticut + 11 more
Source: ClinicalTrials.gov public record
Updated Nov 4, 2021 · Synced Oct 19, 2026, 8:24 PM EDT
Completed Phase 2Phase 3 Interventional Results available

Tolerability and Safety of IGI, 10% With rHuPH20 in PIDD

NCT01485796
View directory record Official record
Conditions
Primary Immunodeficiency Diseases (PID)
Interventions
Immune Globulin Infusion (Human), 10%, Recombinant human hyaluronidase
Biological
Lead sponsor
Baxalta now part of Shire
Industry
Eligibility
2 Years and older
Enrollment
54 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
10
States / cities
Irvine, California • Thornton, Colorado • North Palm Beach, Florida + 7 more
Source: ClinicalTrials.gov public record
Updated May 19, 2021 · Synced Oct 19, 2026, 8:24 PM EDT
Terminated Phase 2 Interventional Results available

Fludarabine Phosphate, Cyclophosphamide, Total Body Irradiation, and Donor Stem Cell Transplant in Treating Patients With Blood Cancer

NCT03333486
View directory record Official record
Conditions
Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Acute Leukemia in Remission, Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia, Acute Myeloid Leukemia With FLT3/ITD Mutation, Acute Myeloid Leukemia With Gene Mutations, Aplastic Anemia, B-Cell Non-Hodgkin Lymphoma, CD40 Ligand Deficiency, Chronic Granulomatous Disease, Chronic Leukemia in Remission, Chronic Lymphocytic Leukemia, Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Chronic Myelomonocytic Leukemia, Chronic Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Congenital Amegakaryocytic Thrombocytopenia, Congenital Neutropenia, Congenital Pure Red Cell Aplasia, Glanzmann Thrombasthenia, Immunodeficiency Syndrome, Myelodysplastic Syndrome, Myelofibrosis, Myeloproliferative Neoplasm, Paroxysmal Nocturnal Hemoglobinuria, Plasma Cell Myeloma, Polycythemia Vera, Recurrent Non-Hodgkin Lymphoma, Refractory Non-Hodgkin Lymphoma, Secondary Acute Myeloid Leukemia, Secondary Myelodysplastic Syndrome, Severe Aplastic Anemia, Shwachman-Diamond Syndrome, Sickle Cell Disease, T-Cell Non-Hodgkin Lymphoma, Thalassemia, Waldenstrom Macroglobulinemia, Wiskott-Aldrich Syndrome
Interventions
Cyclophosphamide, Fludarabine Phosphate, Laboratory Biomarker Analysis, Peripheral Blood Stem Cell Transplantation, Total-Body Irradiation
Drug · Other · Procedure + 1 more
Lead sponsor
Roswell Park Cancer Institute
Other
Eligibility
1 Year to 75 Years
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2023
U.S. locations
1
States / cities
Buffalo, New York
Source: ClinicalTrials.gov public record
Updated Jul 4, 2025 · Synced Oct 19, 2026, 8:24 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Alcohol Monitor Validation

NCT03617705
View directory record Official record
Conditions
Human Immunodeficiency Virus (HIV)
Interventions
Skyn Monitor Lab Session 1, Skyn Monitor Field Test with EMA App, Skyn Monitor Lab Session 2
Device
Lead sponsor
University of Florida
Other
Eligibility
21 Years to 64 Years
Enrollment
49 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2022
U.S. locations
2
States / cities
Gainesville, Florida
Source: ClinicalTrials.gov public record
Updated Jun 28, 2023 · Synced Oct 19, 2026, 8:24 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers

Immunologic Memory (Supp. of ATN 024)

NCT00142753
View directory record Official record
Conditions
HIV Infections
Interventions
Engerix B, Twinrix for ATN 024, Recombivax, Twinrix for ATN 025
Biological
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
12 Years to 25 Years
Enrollment
95 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005 – 2007
U.S. locations
4
States / cities
Los Angeles, California • San Franciso, California • Washington D.C., District of Columbia + 1 more
Source: ClinicalTrials.gov public record
Updated Feb 28, 2017 · Synced Oct 19, 2026, 8:24 PM EDT
Active, not recruiting Phase 2 Interventional

Senolytics Treatment of Interstitial Lung Disease in Common Variable Immunodeficiency

NCT05593588
View directory record Official record
Conditions
Common Variable Immunodeficiency, Interstitial Lung Disease Due to Systemic Disease
Interventions
Fisetin, Placebo
Drug
Lead sponsor
Avni Joshi
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Jun 30, 2026 · Synced Oct 19, 2026, 8:24 PM EDT
Completed Not applicable Interventional

Pilot Study of the Effects of Exercise on Aging Among Older Persons With HIV

NCT01860261
View directory record Official record
Conditions
HIV
Interventions
Aerobic and Strength Training Intervention
Behavioral
Lead sponsor
University of California, San Francisco
Other
Eligibility
50 Years and older
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Nov 8, 2023 · Synced Oct 19, 2026, 8:24 PM EDT
Completed Phase 1 Interventional

A Phase I/II, Open Label Study to Evaluate the Antiviral Potential of Combination Zidovudine and 2' 3'-Dideoxyinosine (Didanosine) in Patients With Asymptomatic HIV Disease

NCT00000656
View directory record Official record
Conditions
HIV Infections
Interventions
Zidovudine, Didanosine
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
12 Years and older
Enrollment
116 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Ends 1993
U.S. locations
5
States / cities
Palo Alto, California • Washington D.C., District of Columbia • Pittsburgh, Pennsylvania + 1 more
Source: ClinicalTrials.gov public record
Updated Nov 3, 2021 · Synced Oct 19, 2026, 8:24 PM EDT
Completed Phase 1 Interventional

Effects of Treatment With Aprepitant (Emend®) in HIV Infected Individuals. 375 mg Dose

NCT01300988
View directory record Official record
Conditions
HIV Infection
Interventions
Aprepitant, Aprepitant placebo
Drug
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years and older
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2013
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jun 3, 2016 · Synced Oct 19, 2026, 8:24 PM EDT
Not listed No phase listed Observational Accepts healthy volunteers

Transgender Cohort Study of Gender Affirmation and HIV-related Health

NCT03595956
View directory record Official record
Conditions
HIV/AIDS, STI, Gender Dysphoria, Transsexualism, Gender Identity, Depression, Anxiety
Interventions
Medical gender affirmation
Other
Lead sponsor
Fenway Community Health
Other
Eligibility
18 Years and older
Enrollment
4,500 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2021
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Nov 18, 2020 · Synced Oct 19, 2026, 8:24 PM EDT
Completed Phase 2 Interventional

A Randomized, Parallel Arm, Comparative, Open Label, Multicenter Study of the Activity and Safety of Two Formulations of Saquinavir in Combination With Other Antiretroviral Drugs

NCT00002162
View directory record Official record
Conditions
HIV Infections
Interventions
Saquinavir, Lamivudine, Stavudine, Zidovudine, Zalcitabine, Didanosine
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
13 Years and older
Enrollment
140 participants
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
23
States / cities
Phoenix, Arizona • Los Angeles, California • Palo Alto, California + 16 more
Source: ClinicalTrials.gov public record
Updated Jun 24, 2005 · Synced Oct 19, 2026, 8:24 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

GSK1349572 Drug Interaction Study With Efavirenz

NCT01098526
View directory record Official record
Conditions
Infections, Human Immunodeficiency Virus and Herpesviridae
Interventions
GSK1349572, Efavirenz
Drug
Lead sponsor
ViiV Healthcare
Industry
Eligibility
18 Years to 65 Years
Enrollment
12 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010
U.S. locations
1
States / cities
Buffalo, New York
Source: ClinicalTrials.gov public record
Updated Sep 25, 2017 · Synced Oct 19, 2026, 8:24 PM EDT
Completed Phase 1Phase 2 Interventional Accepts healthy volunteers

Safety of and Immune Response to a Hepatitis B Virus Vaccine Given With a Booster (CpG7909 ODN) in HIV Infected and HIV Uninfected People

NCT00100633
View directory record Official record
Conditions
HIV Infections, Hepatitis B
Interventions
CpG7909 oligodeoxynucleotides (ODN), Hepatitis B virus vaccine
Drug · Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 65 Years
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2004 – 2007
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Oct 1, 2008 · Synced Oct 19, 2026, 8:24 PM EDT
Active, not recruiting No phase listed Observational

Mechanisms of Cardiac Dysfunction in HIV and the Effect of Statins: A Cardiac MRI Study

NCT03238755
View directory record Official record
Conditions
HIV Infections
Interventions
Cardiac MRI/MRS
Other
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
40 Years to 75 Years
Enrollment
129 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2028
U.S. locations
3
States / cities
Los Angeles, California • Boston, Massachusetts • Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Oct 7, 2026 · Synced Oct 19, 2026, 8:24 PM EDT
Not yet recruiting Not applicable Interventional Accepts healthy volunteers

Combating HIV Stigma in Healthcare Settings: A Standardized Patient Approach

NCT06975176
View directory record Official record
Conditions
Hiv
Interventions
Stigma reduction intervention
Behavioral
Lead sponsor
University of Minnesota
Other
Eligibility
18 Years to 99 Years
Enrollment
155 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2028
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Sep 3, 2026 · Synced Oct 19, 2026, 8:24 PM EDT